Steven Barash is a dynamic manufacturing information systems thought leader spearheading digital manufacturing initiatives at L7 Informatics. Steven holds an established software implementation portfolio of regulated technology solutions in the cell and gene therapy manufacturing industry. Steven is committed to end-to-end automation of complex cell gene manufacturing operations to deliver personalized treatments to patients. He is focused on delivering unified enterprise data solutions to ease operational complexities, improve product quality, and digitally scale GMP commercial operations. Before L7 Informatics, Steven held various leadership and engineering roles at Charles River Labs, Cognate BioServices, TRC, Juno Therapeutics, Regeneron Pharmaceuticals, and AxoGen. Steven has a B.S. in Chemical Engineering from the University of Florida where he focused on translational research in immunomodulatory drug efficacy in preclinical animal models.
Everyday, I have the delightful honor to work closely with Life Sciences, Biotech, Diagnostics, CROs, and CDMOs dedicated to advancing healthcare, medicine, and patient care through use of digital tools and technologies. By having a personal experience where my family and I were first hand impacted by the impacts of debilitating diseases with insufficient nor non-curative treatments available yet a successful pipeline of treatments in the works. I am on a personal mission to enable scientists, engineers, and organizations to successfully adopt digitalization to enable their pipelines of treatments, diagnostics, and methods to accelerate their speeds to market for novel products making a direct impact on patient care. Life Sciences Digitalization is a complex, intricate initiative and with my firsthand experience as an L7 customer and ESP implementer, I have the direct experience to consult with customers to define their digital roadmap, develop business cases and digital strategies, and implement bite-size chunks of digital capabilities and tools. Through digitalization, I have experienced increase in business velocity, reduce technology transfer timelines, and accelerated new product introductions thereby making a direct impact on improving patient care and patient outcomes.
&nsbp;
